Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Incretin-based therapies are important addition to our armamentarium for the treatment of
type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are commonly used in combination
with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for …

Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1
RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM) …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …

Purpose The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment
of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed …